Corcept Therapeutics Incorporated Stock Price on November 22, 2024
| CORT Stock | USD 57.68 0.92 1.57% |
Below is the normalized historical share price chart for Corcept Therapeutics Incorporated extending back to April 14, 2004. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Corcept Therapeutics stands at 57.68, as last reported on the 1st of December, with the highest price reaching 59.12 and the lowest price hitting 57.43 during the day.
If you're considering investing in Corcept Stock, it is important to understand the factors that can impact its price. Corcept Therapeutics appears to be very steady, given 3 months investment horizon. Corcept Therapeutics secures Sharpe Ratio (or Efficiency) of 0.31, which signifies that the company had a 0.31% return per unit of risk over the last 3 months. By analyzing Corcept Therapeutics' technical indicators, you can evaluate if the expected return of 0.85% is justified by implied risk. Please makes use of Corcept Therapeutics' Downside Deviation of 2.23, mean deviation of 2.15, and Risk Adjusted Performance of 0.2328 to double-check if our risk estimates are consistent with your expectations.
At this time, Corcept Therapeutics' Total Stockholder Equity is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 652.6 M in 2024, whereas Other Stockholder Equity is likely to drop slightly above 98.3 M in 2024. . At this time, Corcept Therapeutics' Price Earnings Ratio is comparatively stable compared to the past year. Price Book Value Ratio is likely to gain to 6.97 in 2024, whereas Price To Sales Ratio is likely to drop 6.62 in 2024. Corcept Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 14th of April 2004 | 200 Day MA 34.5094 | 50 Day MA 49.8592 | Beta 0.455 |
Corcept |
Sharpe Ratio = 0.3067
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CORT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.79 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.85 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.31 actual daily | 24 76% of assets perform better |
Based on monthly moving average Corcept Therapeutics is performing at about 24% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Corcept Therapeutics by adding it to a well-diversified portfolio.
Price Book 9.4601 | Enterprise Value Ebitda 39.2363 | Price Sales 9.7681 | Shares Float 85.7 M | Wall Street Target Price 74.9 |
Corcept Therapeutics Main Headline on 22nd of November 2024
Corcept Shares Rise More Than 60 percent in Three Months Her... by finance.yahoo.com
CORTs Cushings syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushings syndrome will be filed shortly.
Corcept Therapeutics Valuation on November 22, 2024
It is possible to determine the worth of Corcept Therapeutics on a given historical date. On November 22, 2024 Corcept was worth 56.2 at the beginning of the trading date compared to the closed value of 57.54. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Corcept Therapeutics stock. Still, in general, we apply an absolute valuation method to find Corcept Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Corcept Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Corcept Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 56.16 | 57.24 | 55.34 | 55.92 | 599,844 | |
11/22/2024 | 56.20 | 57.71 | 56.14 | 57.54 | 676,084 |
| 57.62 | 59.54 | 57.50 | 59.03 | 1,501,395 |
| Backtest Corcept Therapeutics | | | Corcept Therapeutics History | | | Corcept Therapeutics Valuation | Previous | Next |
Corcept Therapeutics Trading Date Momentum on November 22, 2024
| On November 25 2024 Corcept Therapeutics Incorporated was traded for 59.03 at the closing time. The top price for the day was 59.54 and the lowest listed price was 57.50 . The trading volume for the day was 1.5 M. The trading history from November 25, 2024 was a factor to the next trading day price appreciation. The overall trading delta against the next closing price was 2.59% . The overall trading delta against the current closing price is 1.89% . |
Corcept Therapeutics Fundamentals Correlations and Trends
By evaluating Corcept Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Corcept Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Corcept financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Corcept Therapeutics Stock history
Corcept Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Corcept is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Corcept Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Corcept Therapeutics stock prices may prove useful in developing a viable investing in Corcept Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 111.7 M | 83.1 M | |
| Net Income Applicable To Common Shares | 116.5 M | 122.3 M |
Corcept Therapeutics Quarterly Net Working Capital |
|
Corcept Therapeutics Stock Technical Analysis
Corcept Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Corcept Therapeutics Period Price Range
Low | December 1, 2024
| High |
0.00 | 0.00 |
Corcept Therapeutics Incorporated cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Corcept Therapeutics December 1, 2024 Market Strength
Market strength indicators help investors to evaluate how Corcept Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Corcept Therapeutics shares will generate the highest return on investment. By undertsting and applying Corcept Therapeutics stock market strength indicators, traders can identify Corcept Therapeutics Incorporated entry and exit signals to maximize returns
Corcept Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Corcept Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Corcept Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Corcept to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.2328 | |||
| Jensen Alpha | 0.6827 | |||
| Total Risk Alpha | 0.3469 | |||
| Sortino Ratio | 0.3074 | |||
| Treynor Ratio | 0.8016 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.